Non-Viral Gene Delivery Technologies Market Growth Outlook Reveals A CAGR Of 15.1% And A Market Value Of $9.26 Billion By 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Non-Viral Gene Delivery Technologies Market Size, Value And Growth Trends Through 2030
The market for non-viral gene delivery technologies has experienced substantial expansion over the last few years. Projections indicate it will rise from $4.57 billion in 2025 to $5.28 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.5%. This historic growth was driven by factors such as a dependence on viral delivery methods, a constrained supply of non-viral transfection reagents, heightened interest in gene therapy research, greater utilization of plasmid DNA and mRNA delivery kits, and the adoption of electroporation alongside physical delivery techniques.
The market for non-viral gene delivery technologies is projected to expand rapidly over the coming years. By 2030, its value is anticipated to reach $9.26 billion, reflecting a compound annual growth rate (CAGR) of 15.1%. This forecasted growth is driven by the development of advanced lipid and polymer nanoparticles, the spread of pre-formulated nanoparticle technologies, higher investment in gene editing and RNAi therapeutics, growing demand for personalized gene therapy solutions, and the integration of high-throughput and automated delivery platforms. Key trends shaping the period include an increasing reliance on lipid-based and polymer-based non-viral delivery systems, the rise of CRISPR and Cas9 gene editing applications, greater demand for RNAi and DNA vaccine delivery platforms, expansion of both ex-vivo and in-vivo gene therapy studies, and the creation of cell-specific and targeted gene delivery reagents.
Download A Free Sample Report For Comprehensive Market Insights:
Non-Viral Gene Delivery Technologies Market Growth Momentum: Which Factors Are Influencing Demand?
The expansion of the non-viral gene delivery technologies market is being propelled by the growing appetite for personalized medicine. This medical strategy tailors prevention, diagnosis, and treatment to an individual’s genetic makeup, lifestyle, and environmental context. Its rise is fueled by innovations in genomic sequencing, which enable more precise diagnostics, targeted therapies, and better outcomes custom-fit for each patient. The heightened emphasis on personalized medicine is boosting demand for non-viral gene delivery technologies, as these methods offer safer and more versatile ways to deliver therapeutic genes that match a person’s genetic profile, sidestepping the hazards associated with viral vectors. As an example, in February 2024, the Personalized Medicine Coalition—a US-based nonprofit—announced that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to six in 2022. Hence, the increasing adoption of personalized medicine is driving growth in the non-viral gene delivery technologies market.
Non-Viral Gene Delivery Technologies Market Segment Outlook: Which Categories Are Expanding The Fastest?
The non-viral gene delivery technologies market covered in this report is segmented –
1) By Product: Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles
2) By Delivery: In-Vitro, In-Vivo, Ex-Vivo
3) By Technology: Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles
4) By Application: Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression
5) By End-Use: Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses
Subsegments:
1) By Reagents And Kits: Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents
2) By Delivery Devices: Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems
3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles
Non-Viral Gene Delivery Technologies Market Trends Reshaping Industry Growth
Major players in the non-viral gene delivery market are increasingly prioritizing the development of innovative solutions, like non-viral genetic medicine platforms, to enhance both the safety and effectiveness of gene therapies. A non-viral genetic medicine platform is a technique that delivers therapeutic genes or nucleic acids into cells without relying on viruses, thereby minimizing immune responses and safety risks while enabling precise and controlled gene therapy administration for a range of diseases. For example, in October 2023, Generation Bio Co., a U.S.-based biotechnology firm specializing in genetic medicine, introduced immune-quiet DNA (iqDNA). This novel DNA represents an optimized variant of their closed-ended DNA (ceDNA) that avoids detection by the innate immune system, demonstrating cytokine levels and tolerability comparable to those of chemically modified mRNA in both mice and non-human primates when administered using their lipid nanoparticle (LNP) delivery system. Thanks to iqDNA’s improved tolerability, Generation Bio is now advancing it as the primary DNA cargo across all its initiatives, including its lead program targeting hemophilia A.
Non-Viral Gene Delivery Technologies Market Key Companies And Competitive Benchmarking
Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.
Access The Complete Non-Viral Gene Delivery Technologies Market Report:
Non-Viral Gene Delivery Technologies Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the non-viral gene delivery technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
